NCT05567289 Precision Medicine for Stem Cell Transplantation
| NCT ID | NCT05567289 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Manchester |
| Condition | Haematopoietic Stem Cell Transplantation |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-06-06 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2023-06-06 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A study of patients undergoing haematopoietic stem cell transplantation, a procedure in which patients are infused with stem cells from a donor, resulting in a new immune system that eliminates cancer or replaces diseased bone marrow. This study aims to develop new blood tests that predict the onset of acute graft-versus-host disease (aGvHD) and leukaemia relapse, two life-threatening complications that frequently limit the success of treatment. Predictive tests would allow doctors to individualise prophylaxis and intervene early to abort complications before they develop. The study will also create a large collection of clinically annotated blood samples from 300 transplant recipients to support future research and provide a resource to the transplant research community.
Eligibility Criteria
Inclusion Criteria: * Any recipient of allogeneic haematopoietic stem cell transplantation (HSCT) * Children/infants may participate, there is no age restriction * Patients participating in other clinical trials remain eligible Exclusion Criteria: * Weight \<5kg * Recipients of autologous stem cell transplants
Contact & Investigator
Mark Williams
PRINCIPAL INVESTIGATOR
CRUK Manchester Institute
Frequently Asked Questions
Who can join the NCT05567289 clinical trial?
This trial is open to participants of all sexes, studying Haematopoietic Stem Cell Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05567289 currently recruiting?
Yes, NCT05567289 is actively recruiting participants. Contact the research team at mark.williams-4@cruk.manchester.ac.uk for enrollment information.
Where is the NCT05567289 trial being conducted?
This trial is being conducted at Manchester, United Kingdom, Manchester, United Kingdom, Manchester, United Kingdom.
Who is sponsoring the NCT05567289 clinical trial?
NCT05567289 is sponsored by University of Manchester. The principal investigator is Mark Williams at CRUK Manchester Institute. The trial plans to enroll 300 participants.